Caricamento...
Curaxin CBL0137 has the potential to reverse HIV-1 latency
A cure for human immunodeficiency virus type-1 (HIV-1) has been hampered by the limitation of current combination antiretroviral therapy (cART) to address the latent reservoirs in HIV-1 patients. One strategy proposed to eradicate these reservoirs is the “shock and kill” approach, where latency-reve...
Salvato in:
| Pubblicato in: | J Med Virol |
|---|---|
| Autori principali: | , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6599568/ https://ncbi.nlm.nih.gov/pubmed/30989696 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jmv.25487 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|